Skip to content
DataLookout
Menu

NCT07546812

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment closed, study ongoing
    • Study sites: 15 to 16
  2. Notable Eligibility criteria expanded, about 19 words
    • Trial sites expanded: 12 → 15 locations
  3. Minor Trial sites expanded: 4 → 12 locations
    • Start date changed from estimate of Jul 2026 to Aug 7, 2026
    v4
  4. Notable Start date: May 2026 to Jul 2026
    • Trial sites expanded: 1 → 4 locations
    v3
  5. Notable Recruitment opened
    • Eligibility criteria expanded, about 20 words
    • Study sites: 0 to 1
    • Start date: Apr 2026 to May 2026
    v2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Objective Response Rate (ORR)
Timeframe: Up to 4 years

Secondary (9)

Duration of Response (DOR)
Progression-Free Survival (PFS)
Overall Survival (OS)
Percentage of Participants Experiencing Treatment-Emergent Adverse Event (TEAEs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
Percentage of Participants Experiencing Clinical Laboratory Abnormalities According to the NCI CTCAE v5.0
Show 4 moreShow less
Pharmacokinetic (PK) Parameter: Serum concentration of DEN
PK Parameter: Cmax for Denikitug
PK Parameter: AUCall for Denikitug
Percentage of Participants who Developed Treatment-Emergent Antidrug Antibody (ADA) Against Denikitug

Arms and interventions

Part 1: Arm A: DEN (Dose A) and NIVOExperimental

Participants will receive DEN Dose A as an IV infusion in combination with NIVO as an IV infusion.

Part 1: Arm B: DEN (Dose B) and NIVOExperimental

Participants will receive DEN Dose B as an IV infusion in combination with NIVO as an IV infusion.

Part 1: Arm C: DEN (Dose B)Experimental

Participants will receive DEN Dose B as an IV infusion.

Part 2: Arm D: Safety Run-in (SRI) CohortExperimental

Participants will receive DEN in combination with ramucirumab (RAM) and paclitaxel (PAC). If dose for DEN is deemed safe during the SRI Cohort, the study will move forward into the Expansion Period.

Part 2: Arm D: Expansion CohortExperimental

If DEN dose is deemed safe in Arm D: SRI Cohort, participants will receive DEN at recommended dose as an IV infusion in combination with RAM and PAC.

Drugs: Denikitug, Nivolumab, Ramucirumab, Paclitaxel

Sites

16 sites in 5 countries

Australia 5, Spain 4, United States 4, France 2, South Korea 1